Missing content? – Request curation!
Request curation for specific Genes, variants, or PubMed publications.
Have questions, comments or suggestions? - Let us know!
Email us at : email@example.com
|Therapy Name||Durvalumab + Mogamulizumab|
|Drug Name||Trade Name||Synonyms||Drug Classes||Drug Description|
|Durvalumab||Imfinzi||MEDI4736||Immune Checkpoint Inhibitor 98 PD-L1/PD-1 antibody 67||Imfinzi (durvalumab) is a monoclonal antibody that binds to and inhibits PD-L1 (CD274), potentially resulting in increased immune response to tumors (PMID: 25943534, PMID: 28214651). Imfinzi (durvalumab) is FDA approved for use in patients with urothelial carcinoma and unresectable, stage III non-small cell lung cancer, and in combination with etoposide and carboplatin or cisplatin in patients with extensive stage small cell lung cancer (FDA.gov).|
|Mogamulizumab||Poteligeo||KW-0761|Mogamulizumab-kpkc||Poteligeo (mogamulizumab-kpkc) is a monoclonal antibody that binds to and inhibits C-C chemokine receptor 4 (CCR4) signaling, which leads to inhibition of Tregs and enhancement of host antitumor immunity (PMID: 25496334). Poteligeo (mogamulizumab-kpkc) is FDA approved for adult patients with relapsed or refractory mycosis fungoides or Sezary syndrome (FDA.gov).|
|Molecular Profile||Indication/Tumor Type||Response Type||Therapy Name||Approval Status||Evidence Type||Efficacy Evidence||References|
|Unknown unknown||alveolar soft part sarcoma||not applicable||Durvalumab + Mogamulizumab||Case Reports/Case Series||Actionable||In a Phase I trial, a patient with alveolar soft part sarcoma achieved a partial response after 3.68 months with a response duration of 10.6 months following treatment with the combination of Poteligeo (mogamulizumab-kpkc) and Imfinzi (durvalumab) (PMID: 32586937; NCT02301130).||32586937|
|Unknown unknown||Advanced Solid Tumor||no benefit||Durvalumab + Mogamulizumab||Phase I||Actionable||In a Phase I trial, the combination of Poteligeo (mogamulizumab-kpkc) and Imfinzi (durvalumab) demonstrated tolerability in patients with advanced solid tumors, but resulted in minimal efficacy, with an objective response rate of 5.3% (1/19, one partial response in a patient with alveolar soft part sarcoma), median progression-free survival of 1.9 months, and median overall survival of 8.9 months (PMID: 32586937; NCT02301130).||32586937|
|Clinical Trial||Phase||Therapies||Title||Recruitment Status||Covered Countries||Other Countries|